|
|
|
| Factors affecting direct-acting antiviral agents therapy among cases with hepatitis C virus infection in Zhejiang Province |
| YANG Jiezhe, ZHOU Xin, JIANG Jun, XU Yun, CHAI Chengliang, CHEN Lin, CHENG Wei
|
| Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China |
|
|
|
|
Abstract Objective To analyze the factors affecting direct-acting antiviral (DAA) therapy among cases with hepatitis C virus (HCV) infection in Zhejiang Province, so as to provide evidence for optimizing local HCV prevention and treatment strategies and improving DAA treatment coverage. Methods Eight counties (cities, districts) in Zhejiang Province were selected as survey sites. Consecutive sampling was used to enroll HCV cases reported from November 2022 to June 2024. Demographic information, diagnosis and treatment status, DAA therapy, and awareness of relevant medical insurance policies were collected through questionnaire surveys. Factors affecting DAA therapy among cases with HCV infection were analyzed using a multivariable logistic regression model. Results A total of 412 questionnaires were distributed, and 404 valid questionnaires were collected, with an effective rate of 98.06%. There were 291 males (72.03%) and 113 females (27.97%). The median age was 49.00 (interquartile range, 11.00) years. A total of 303 cases received DAA therapy, with a proportion of 75.00%. Multivariable logistic regression analysis showed that HCV cases aged 40-<50 years (OR=3.469, 95%CI: 1.228-9.345) and with per capita monthly household income >3 000 yuan (>3 000-5 000 yuan, OR=3.198, 95%CI: 1.597-6.403; >5 000 yuan, OR=5.391, 95%CI: 2.230-13.033) had higher likelihood of receiving DAA therapy. HCV cases diagnosed in non-infectious disease departments (OR=0.334, 95%CI: 0.173-0.643), concerned about economic burden of DAA therapy (OR=0.309, 95%CI: 0.160-0.599), and unaware of HCV payment policy by disease type (OR=0.262, 95%CI: 0.111-0.622) had lower likelihood of receiving DAA therapy. Conclusions The proportion of DAA therapy among cases with HCV infection in Zhejiang Province is relatively high. Age, per capita monthly household income, department of diagnosis, concerns about DAA therapy, and medical insurance/payment policies are factors influencing DAA therapy among cases with HCV infection.
|
|
Received: 31 October 2025
Revised: 28 February 2026
Published: 23 March 2026
|
|
|
|
|
|
[1] LI J,PANG L,DING G W,et al.Seroepidemiology of hepatitis C virus infection in people aged 1-69 years in China:a national,cross-sectional study[J].Lancet Public Health,2025,10(12):1036-1044.
[2] 李健,刘中夫,严俊.贯彻落实工作方案推进消除丙肝公共卫生危害进程[J].中国艾滋病性病,2024,30(7):667-669.
[3] World Health Organization.Global health sector strategy on viral hepatitis2016-2021[EB/OL].[2026-02-28].https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en.
[4] LI J,PANG L,LIU Z F.Interpretation of the national action plan for eliminating hepatitis C as a public health threat(2021-2030)[J].China CDC Weekly,2022,4(29):627-630.
[5] D'AMBROSIO R,DEGASPERI E,COLOMBO M,et al.Direct-acting antivirals:the endgame for hepatitis C?[J].Curr Opin Virol,2017,24:31-37.
[6] 中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2022年版)[J].中华肝脏病杂志,2022,30(12):1332-1348.
[7] 刘春桃,张琬悦,张小斌,等.云南两地区HCV抗体阳性者丙肝防治知识知晓率及诊疗现状[J].中国公共卫生管理,2019,35(4):522-524,527.
[8] World Health Organization.Global hepatitis report2024:action for access in low-and middle-income countries[R/OL].[2026-02-28].https://www.who.int/publications/i/item/9789240091672.
[9] 程伟,周欣,杨介者,等.浙江省试点县区新报告丙型肝炎病例强化管理探索与实践[J].中国艾滋病性病,2024,30(7):743-744.
[10] 陈仲丹. 全球丙型肝炎消除的进展、挑战及应对[J].中华肝脏病杂志,2020,28(10):812-816.
[11] 后永春,王玉芹,魏巍,等.上海市普陀区丙型肝炎患者抗病毒治疗的影响因素分析[J].中国艾滋病性病,2025,31(4):378-383.
[12] 徐朋,虞接军,张琬悦,等.基于Andersen模型探讨既往报告丙型肝炎患者抗病毒治疗的相关因素研究[J].中华肝脏病杂志,2023,31(1):49-55.
[13] 张亚丽,马琳,孙悦,等.河北省临床医生丙型肝炎知识知晓情况调查及影响因素分析[J].现代预防医学,2025,52(19):3637-3642.
[14] 苏兴芳,夏淼,张小斌,等.云南省医务人员丙型肝炎防治知识知晓情况分析[J].皮肤病与性病,2024,46(4):257-262.
[15] 侯志刚,葛锐,张倩倩,等.嘉兴市临床医生丙型肝炎防治知识调查[J].预防医学,2023,35(7):636-639.
[16] 汤杨,庞琳,李健.丙型肝炎知识知晓研究进展[J].中国预防医学杂志,2024,25(10):1337-1340. |
|
|
|
